Description of Business (Tables)

6 Months Ended

Jun. 30, 2022

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Schedule of Restated Condensed Consolidated Balance Sheet

Restated Condensed Consolidated Balance Sheet (unaudited)


	As of June 30, 2022
	As reported			As adjusted - (a)			As adjusted - (b)			As adjusted - (c)		As adjusted - (d)			As adjusted - Total			As restated
Accrued expenses and other current liabilities	$	4,428		$	—		$	1,590		$	—	$	—		$	1,590		$	6,018
Total current liabilities		11,279			—			1,590			—		—			1,590			12,869
Derivative warrant liabilities		8,944			—			—			—		3,204			3,204			12,148
Earn-out liabilities		8,925			(1,069	)		—			—					(1,069	)		7,856
Total liabilities		54,765			(1,069	)		1,590			—		3,204			3,725			58,490
Additional paid-in capital		401,290			6,170			—			—		(445	)		5,725			407,015
Accumulated deficit		(227,575	)		(5,101	)		(1,590	)		—		(2,759	)		(9,450	)		(237,025	)
Total stockholders’ equity (deficit)		173,825			1,069			(1,590	)		—		(3,204	)		(3,725	)		170,100

Schedule of Restated Condensed Consolidated Statement Of Operations

Restated Condensed Consolidated Statements of Operations (unaudited)


	For the Three Months Ended June 30, 2022
	As reported			As adjusted - (a)			As adjusted - (b)			As adjusted - (c)			As adjusted - (d)		As adjusted - Total			As restated
Research and development	$	12,634		$	—		$	113		$	—		$	—	$	113		$	12,747
Total operating expenses		26,906			—			113			—			—		113			27,019
Loss from operations		(25,645	)		—			(113	)		—			—		(113	)		(25,758	)
Change in fair value of derivate warrant liabilities		8,687			—			—			(1,331	)		624		(707	)		7,980
Change in fair value of earn-out liability		8,024			(1,458	)		—			—			—		(1,458	)		6,566
Total other income (expense), net		15,671			(1,458	)		—			(1,331	)		624		(2,165	)		13,506
Net loss	$	(9,974	)	$	(1,458	)	$	(113	)	$	(1,331	)	$	624	$	(2,278	)	$	(12,252	)
Net loss per share attributed to common stockholders - basic and diluted	$	(0.09	)												$	(0.02	)	$	(0.11	)


	For the Six Months Ended
	June 30, 2022
	As reported			As adjusted - (a)			As adjusted - (b)			As adjusted - (c)		As adjusted - (d)			As adjusted - Total			As restated
Research and development	$	25,083		$	—		$	1,590		$	—	$	—		$	1,590		$	26,673
Total operating expenses		52,391			—			1,590			—		—			1,590			53,981
Loss from operations		(49,440	)		—			(1,590	)		—		—			(1,590	)		(51,030	)
Change in fair value of derivate warrant liabilities		14,509			—			—			—		(2,759	)		(2,759	)		11,750
Change in fair value of earn-out liability		17,658			(5,101	)		—					—			(5,101	)		12,557
Total other income (expense), net		28,996			(5,101	)		—			—		(2,759	)		(7,860	)		21,136
Net loss	$	(20,444	)	$	(5,101	)	$	(1,590	)	$	—	$	(2,759	)	$	(9,450	)	$	(29,894	)
Net loss per share attributed to common stockholders - basic and diluted	$	(0.24	)												$	(0.12	)	$	(0.36	)

Schedule of Restated Condensed Consolidated Statement of Redeemable Convertible Preferred Stock and Stockholder's (Deficit) Equity

Restated Condensed Consolidated Statement of Redeemable Convertible Preferred Stock and Stockholder’s (Deficit) Equity (unaudited) as of June 30, 2022


	For the Six Months Ended June 30, 2022
	As reported			As adjusted - (a)			As adjusted - (b)			As adjusted - (c)		As adjusted - (d)			As adjusted - Total			As Restated
Additional Paid-In Capital	$	401,290		$	6,170		$	—		$	—	$	(445	)	$	5,725		$	407,015
Accumulated deficit		(227,575	)		(5,101	)		(1,590	)		—		(2,759	)		(9,450	)		(237,025	)
Total Stockholders’ (Deficit) Equity		173,825			1,069			(1,590	)		—		(3,204	)		(3,725	)		170,100

Schedule of Restated Condensed Consolidated Statement of Cash Flows

Restated Condensed Consolidated Statement of Cash Flows (unaudited)


	For the Six Months Ended June 30, 2022
	As reported			As adjusted - (a)			As adjusted - (b)			As adjusted - (c)		As adjusted - (d)			As adjusted - Total			As restated
Net loss	$	(20,444	)	$	(5,101	)	$	(1,590	)	$	—	$	(2,759	)	$	(9,450	)	$	(29,894	)
Accrued expenses and other current liabilities		967			—			1,590			—		—			1,590			2,557
Change in fair value of derivative warrant liabilities		(14,509	)		—			—			—		2,759			2,759			(11,750	)
Change in fair value of earnout liability		(17,658	)		5,101			—			—		—			5,101			(12,557	)
Net cash used in operating activities		(35,085	)		—			—			—		—			—			(35,085	)